Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)
Part of paid clinical trials in West Haven, Connecticut.
- Sponsor
- VA Office of Research and Development
- Study ID
- NCT07528690
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cirrhosis
- Hepatic Encephalopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Microbiota transplant therapy (MTT) capsules — BIOLOGICALMTP-101-C is manufactured using cGMP protocols in the Molecular and Cellular Therapeutics (MCT) facility at the University of Minnesota.
- Placebo capsule — OTHERPlacebo capsule
Study Details
The goal of this clinical trial is to find out whether changing the microbes in the bowels of Veterans with cirrhosis and hepatic encephalopathy (a condition that affects the brain as a result of liver problems) using capsules made from microbes from healthy people can prevent future episodes of hepatic encephalopathy.
Key Dates
- Start date
- Oct 30, 2026
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2030
- Completion
- Mar 3, 2031
Study Design
- Enrollment
- 162 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: MTTMicrobiota transplant therapy (MTT) capsules
- Placebo Comparator: PlaceboPlacebo capsule
Primary Outcome Measure
Recurrence of Hepatic Encephalopathy (HE) [ Time Frame: 6 months ]
Central Contacts
- Jasmohan S Bajaj, MD MS(804) 675-5802
- Brian C Davis, MD(804) 675-5802
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| CERC (VISN1, West Haven, CT) | West Haven | Connecticut | 06516-2770 | |
| VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX | Dallas | Texas | 75216-7167 | |
| Richmond VA Medical Center, Richmond, VA | Richmond | Virginia | 23249-0001 | Jasmohan S. Bajaj, MD MS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in West Haven, CT
Related Studies
- TReatment for ImmUne Mediated PathopHysiologyPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Los Angeles, California
- Safety and Efficacy of Atorvastatin v. Placebo on HCC RiskPHASE2 · Recruiting · Raymond Chung · Boston, Massachusetts
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisPHASE3 · Recruiting · Can-Fite BioPharma · Dallas, Texas
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434PHASE1 · Recruiting · Vir Biotechnology, Inc. · Rialto, California